Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Tanya R. Myers"'
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Introduction COVID-19 vaccines may be administered with other vaccines during the same healthcare visit. COVID-19 monovalent (Fall 2021) and bivalent (Fall 2022) vaccine recommendations coincided with annual seasonal influenza vaccination. Data descr
Externí odkaz:
https://doaj.org/article/eec475062d8349339ac3d89d097f006d
Autor:
Tanya R. Myers, Michael M. McNeil
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 5, Pp 1175-1178 (2018)
Invasive meningococcal disease, although rare, can present as sudden, life-threatening disease with high risk of mortality or severe long-term sequelae. The main prevention strategy for invasive meningococcal disease in the United States is the routi
Externí odkaz:
https://doaj.org/article/7e00c3d2de4e4d97b578df18a35d6639
Autor:
Tanya R. Myers, Paige L. Marquez, Julianne M. Gee, Anne M. Hause, Lakshmi Panagiotakopoulos, Bicheng Zhang, Isaac McCullum, Charles Licata, Christine K. Olson, Shakeeb Rahman, Sharon B. Kennedy, Matthew Cardozo, Chirayu R. Patel, Liza Maxwell, Joel R. Kallman, David K. Shay, Tom T. Shimabukuro
Publikováno v:
Vaccine. 41:1310-1318
Autor:
Anne M. Hause, Paige Marquez, Bicheng Zhang, John R. Su, Tanya R. Myers, Julianne Gee, Sarada S. Panchanathan, Deborah Thompson, Tom T. Shimabukuro, David K. Shay
Publikováno v:
MMWR. Morbidity and Mortality Weekly Report. 72:39-43
Autor:
Anne M, Hause, Paige, Marquez, Bicheng, Zhang, Tanya R, Myers, Julianne, Gee, John R, Su, Casey, Parker, Deborah, Thompson, Sarada S, Panchanathan, Tom T, Shimabukuro, David K, Shay
Publikováno v:
MMWR. Morbidity and Mortality Weekly Report. 71:1115-1120
Autor:
Anne M, Hause, James, Baggs, Paige, Marquez, Tanya R, Myers, John R, Su, Brandon, Hugueley, Deborah, Thompson, Julianne, Gee, Tom T, Shimabukuro, David K, Shay
Publikováno v:
MMWR. Morbidity and Mortality Weekly Report. 71:1047-1051
On May 17, 2022, the Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine to authorize a homologous* booster dose for children aged 5-11 years ≥5 months after receipt of th
Autor:
Anne M. Hause, James Baggs, Paige Marquez, Winston E. Abara, Babatunde Olubajo, Tanya R. Myers, John R. Su, Deborah Thompson, Julianne Gee, Tom T. Shimabukuro, David K. Shay
Publikováno v:
MMWR. Morbidity and Mortality Weekly Report. 71:347-351
Autor:
Anne M, Hause, James, Baggs, Paige, Marquez, Tanya R, Myers, John R, Su, Phillip G, Blanc, Jane A, Gwira Baumblatt, Emily Jane, Woo, Julianne, Gee, Tom T, Shimabukuro, David K, Shay
Publikováno v:
MMWR. Morbidity and Mortality Weekly Report. 71:249-254
During September 22, 2021-February 6, 2022, approximately 82.6 million U.S. residents aged ≥18 years received a COVID-19 vaccine booster dose.* The Food and Drug Administration (FDA) has authorized a booster dose of either the same product administ
Autor:
James Baggs, Anne M. Hause, Tom T. Shimabukuro, Paige Marquez, Tanya R. Myers, David K. Shay, Julianne Gee
Publikováno v:
Morbidity and Mortality Weekly Report
On August 12, 2021, the Food and Drug Administration (FDA) amended Emergency Use Authorizations (EUAs) for the Pfizer-BioNTech and Moderna COVID-19 vaccines to authorize administration of an additional dose after completion of a primary vaccination s
Autor:
Anne M. Hause, Paige Marquez, Bicheng Zhang, Tanya R. Myers, Julianne Gee, John R. Su, Phillip G. Blanc, Alisha Thomas, Deborah Thompson, Tom T. Shimabukuro, David K. Shay
Publikováno v:
MMWR. Morbidity and mortality weekly report. 71(44)
On August 31, 2022, the Food and Drug Administration (FDA) authorized bivalent formulations of BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines; these vaccines include mRNA encoding the spike protein from the original (ancestral)